

## VIEW POINT

# The importance of influenza vaccination during the COVID-19 pandemic

John McCauley<sup>1</sup>  | Ian G. Barr<sup>2,3</sup>  | Terry Nolan<sup>4,5,6</sup> | Theodore Tsai<sup>7</sup> | Steven Rockman<sup>3,8</sup> | Beverly Taylor<sup>9</sup>

<sup>1</sup>Worldwide Influenza Centre, The Francis Crick Institute, London, UK

<sup>2</sup>WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Melbourne, Victoria, Australia

<sup>3</sup>Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

<sup>4</sup>Vaccine and Immunisation Research Group, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

<sup>5</sup>Department of Infectious Diseases, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia

<sup>6</sup>Vaccine and Immunisation Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia

<sup>7</sup>Takeda Vaccines, Cambridge, Massachusetts, USA

<sup>8</sup>Seqirus Ltd, Parkville, Victoria, Australia

<sup>9</sup>Seqirus Ltd, Liverpool, UK

## Correspondence

Ian G. Barr, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Melbourne, Victoria, Australia.  
Email: ian.barr@influenzacentre.org

## Abstract

The COVID-19 pandemic and the measures taken to mitigate its spread have had a dramatic effect on the circulation patterns of other respiratory viruses, most especially influenza viruses. Since April 2020, the global circulation of influenza has been markedly reduced; however, it is still present in a number of different countries and could pose a renewed threat in the upcoming Northern Hemisphere winter. Influenza vaccination remains the most effective preventive measure that we have at our disposal against influenza infections and should not be ignored for the 2021–2022 season.

## KEYWORDS

coronavirus, COVID-19, influenza, SARS-CoV-2, vaccination

As the 2021 Northern Hemisphere (NH) winter approaches, once again there will be a call for people to be vaccinated against influenza. In 2020, with high levels of COVID-19 infections and strict public health and social interventions dominating in many countries, little or no influenza circulated.<sup>1,2</sup> In the second half of 2021, as countries approach high levels of immunity to COVID-19 through vaccination and/or infection, local and international travels have and will inevitably increase. Enhanced human movement is likely to increase the risk of introduction and spread of influenza and other respiratory diseases from countries where these viruses are circulating. Beyond 2021, the reduction in influenza exposure may increase the population's

susceptibility to new influenza variants even further, leading to more extensive outbreaks of influenza. The Joint Committee on Vaccination and Immunisation (JCVI) in the United Kingdom has recommended a synergistic programme of vaccination for flu and COVID-19 in preparation for this possibility.<sup>3</sup> This commentary explores the need for influenza vaccination taking into account the influence of COVID-19 infection and vaccination.

The COVID-19 pandemic has had an unprecedented impact on humans and society and thereby on the dynamics of human infectious disease, particularly influenza. Non-pharmaceutical interventions (NPIs) resulted in reduced local and international travels, school

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Influenza and Other Respiratory Viruses* published by John Wiley & Sons Ltd.


closures, social distancing and possibly as seen with other respiratory viruses, virus interference,<sup>4</sup> all of which have played a major part in reducing the circulation of human influenza viruses. GISRS (the WHO Global Influenza Surveillance and Response System) monitors worldwide influenza circulation through 147 WHO National Influenza Centres in 126 countries or territories. These laboratories report their data to WHO through two internet platforms both of which are publicly accessible: FluID and FluNet, which collate influenza epidemiological data and the number of influenza viruses detected by virus type and subtype on a weekly basis by country and region—these data are critical for tracking influenza activity and the movement of viruses globally.

WHO reported that influenza activity between September 2020 and January 2021 was mostly present in countries in the tropics and subtropics but was also reported in some countries in the temperate zone of the NH.<sup>5</sup> Of these samples, influenza viruses tested positive in less than 0.2% of the total samples, contrasting sharply with an average of 17% over the previous three seasons prior to the emergence of COVID-19. Nevertheless, new human influenza viruses were still detected in this period. Influenza A(H3N2) viruses emerged in Cambodia and Bangladesh and subsequently spread to other countries, resulting in an update to the composition of the influenza vaccines to be used in the NH 2021/2022 influenza season. Furthermore, antigenically distinct influenza B viruses were detected in China, in parts of West Africa and elsewhere. While influenza circulation has continued at lower levels since the start of 2021, 45 countries have reported 10 or more influenza detections from their sentinel surveillance systems, indicating influenza circulation in that country, albeit limited (Figure 1). At the time of writing, influenza virus circulation in the Southern Hemisphere winter influenza season was still very low,

making it difficult to predict which viruses will emerge in late 2021 and early 2022.

As COVID infections decrease and vaccinations increase worldwide with an accompanying easing of restrictions, there is an opportunity for a resurgence of respiratory viruses to occur. An important lesson of how quickly the resurgence of a respiratory disease can arise was seen recently in Australia with respiratory syncytial virus (RSV). Normally, in the temperate regions of Australia, the seasonality of RSV has been very predictable, with cases rising in April–May each year, peaking in the winter months of June–July, before subsiding in August–September.<sup>6</sup> However, in 2020, the RSV season was atypical, with just a few sporadic cases, but this changed dramatically in late 2020 when a large outbreak occurred in New South Wales, shortly followed by outbreaks in Western Australia, Victoria and Queensland.<sup>7</sup> These outbreaks were very unusual as they occurred in the Spring–Summer period and, significantly, were as severe as those in a normal season, with many paediatric hospitalizations along with adult infections. There has also been a recent outbreak of RSV in the South of France<sup>8</sup> after virtually no RSV cases since late 2019–2020 with similar delayed outbreaks also seen in the United States.<sup>9</sup> While there are differences in the demographics and the global circulation of RSV and influenza, the two share many similarities including the groups that are most vulnerable to infection, the elderly and the very young. Fortunately for influenza, both prophylactic vaccines and antiviral drugs are available, whereas for RSV, there are limited options for the prevention or treatment of disease.

Despite the uncharacteristic decline in influenza circulation worldwide, there is every likelihood that influenza will re-emerge and continue to affect humans at similar levels to that of the past. Low levels of influenza virus transmission in 2020 limited the opportunities to observe clinical features of dual SARS-CoV-2 and seasonal



**FIGURE 1** Countries with >10 lab confirmed influenza cases (■) reported to WHO FluNet in 2021 (<https://www.who.int/tools/flunet> up to 17 September 2021) (n = 45) (world map by [www.freeworldmaps.net](http://www.freeworldmaps.net))

influenza virus infections.<sup>10</sup> Of the few reports, some suggest no difference in the clinical course of dually infected patients compared with those infected with SARS-CoV-2 alone; however, both improved and worse outcomes have been reported.<sup>11–14</sup> From a clinical and public health perspective, the burden on healthcare systems due to epidemics of either virus alone, let alone overlapping epidemics, remains a credible threat. Thus, without intervention, the potential of a ‘syndemic’—a term coined to describe twin synergistic epidemics—due to the cocirculation of influenza and COVID-19 is a serious reality, especially as public health and social measures are relaxed. The presence of two respiratory infections that might not be distinguishable by clinical signs is also important for disease management. Correctly identifying the infecting virus is critical for guidance with respect to treatment, isolation and quarantine.

The US CDC has recently recommended that routine vaccines could be coadministered with authorized COVID-19 vaccines, in order to facilitate the catch-up of missed immunizations.<sup>15</sup> This public health decision was not based on new clinical trial evidence but on the accumulated safety experience of the currently authorized COVID-19 vaccines in millions of recipients, albeit over a relatively short time frame, and the previous experience of safe and effective administration of multiple antigens simultaneously.<sup>16</sup> Safety data on the coadministration of influenza and COVID-19 vaccines are currently being acquired. In the United Kingdom, the JCVI has stated that early evidence on the concomitant administration of COVID-19 and influenza vaccines supports the delivery of both vaccines at the same time where appropriate and that this approach may help to maximize uptake of both vaccines.<sup>3</sup>

One such study carried out as part of a substudy on Seqirus's Flucelvax Quadrivalent and Fluad trivalent vaccines coadministered with the Novavax's COVID-19 vaccine (NVX-CoV2373) as part of their Phase 3 randomized trial showed that coadministration resulted in no change to influenza vaccine immune responses and only a slight reduction in the NVX-CoV2372 immune response.<sup>17</sup> The ComFluCOV clinical trial to assess the safety and immune responses generated when giving COVID-19 and influenza vaccines has reported that all study participants have had their second visit for vaccination and so results are eagerly awaited (<https://comflucov.blogs.bristol.ac.uk/>). For the Southern Hemisphere season, Australian authorities are currently recommending a minimum of 7 days (previously 14 days) between COVID-19 vaccines and influenza vaccines (or vice versa) unless there are extenuating circumstances. As COVID-19 vaccines are further studied and potentially authorized for young children and infants, careful consideration and evidence for safe and effective coadministration with influenza and other routine vaccines is in children also warranted.<sup>18</sup> As the available data to date indicate that coadministration of vaccines is a viable approach, there is benefit in continuing to generate more data to support this as it would facilitate the catch-up of missed vaccinations and would also expedite an efficient outcome for dual protection against influenza and COVID-19.

In summary, even though influenza circulation is currently low globally, influenza viruses are still in circulation and can be rapidly transported when air travel returns leading to increased infections

and potentially epidemics in late 2021 or 2022 as predicted in a recent modelling study.<sup>19</sup> Hence, as the threat of influenza is still present and now more likely to return, influenza vaccination remains the best way to mitigate against infection. So roll up your sleeves once more, just to be sure!

## ACKNOWLEDGEMENT

The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.

## AUTHOR CONTRIBUTIONS

**John McCauley:** Conceptualization. **Ian G. Barr:** Conceptualization; data curation. **Terry Nolan:** Writing and editing. **Theodore Tsai:** Writing and editing. **Steven Rockman:** Conceptualization. **Beverly Taylor:** Conceptualization.

## PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1111/irv.12917>.

## DATA AVAILABILITY STATEMENT

Data are derived from public domain resources.

## ORCID

John McCauley  <https://orcid.org/0000-0002-4744-6347>

Ian G. Barr  <https://orcid.org/0000-0002-7351-418X>

## REFERENCES

1. Tang JW, Bialasiewicz S, Dwyer DE, et al. Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. *J Med Virol* 2021;93(7):4099–4101. <https://doi.org/10.1002/jmv.26964> [published Online First: 2021/03/25].
2. Gomez GB, Mahe C, Chaves SS. Uncertain effects of the pandemic on respiratory viruses. *Science* 2021;372(6546):1043–1044. <https://doi.org/10.1126/science.abh3986> [published Online First: 2021/06/05].
3. UK Government. Independent report. JCVI interim advice: potential COVID-19 booster vaccine programme winter 2021 to 2022. Published 30 June 2021. (Accessed 15 September 2021). Available from: <https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-interim-advice-potential-covid-19-booster-vaccine-programme-winter-2021-to-2022>
4. Nowak MD, Sordillo EM, Gitman MR, et al. Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? *J Med Virol* 2020;92(10):1699–1700. <https://doi.org/10.1002/jmv.25953> [published Online First: 2020/05/01].
5. World Health Organization. Weekly Epidemiological Record 2021; 96:77–88.
6. Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial virus-associated hospitalisations in Australia, 2006–2015. *Med J Aust* 2019;210(10):447–453. <https://doi.org/10.5694/mja2.50159> [published Online First: 2019/05/09].
7. McNab S, Ha Do LA, Clifford V, et al. Changing Epidemiology of Respiratory Syncytial Virus in Australia—delayed re-emergence in Victoria compared to WA/NSW after prolonged lock-down for

- COVID-19. *Clin Infect Dis* 2021. <https://doi.org/10.1093/cid/ciab240> [published Online First: 2021/03/19]
8. Casalegno JS, Ploin D, Cantais A, et al. Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France. *Euro Surveill*. 2021;26(29):2100630. <https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100630>
  9. Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. *Pediatrics* 2021;148(3) doi: <https://doi.org/10.1542/peds.2021-052089> [published Online First: 2021/06/11]
  10. Schirmer MD, Dalca AV, Sridharan R, et al. White matter hyperintensity quantification in large-scale clinical acute ischemic stroke cohorts—the MRI-GENIE study. *Neuroimage Clin* 2019;23: 101884. <https://doi.org/10.1016/j.nicl.2019.101884> [published Online First: 2019/06/15]
  11. Le Hingrat Q, Bouzid D, Choquet C, et al. Viral epidemiology and SARS-CoV-2 co-infections with other respiratory viruses during the first COVID-19 wave in Paris, France. *Influenza Other Respir Viruses* 2021;15(4):425-428. <https://doi.org/10.1111/irv.12853> [published Online First: 2021/04/06]
  12. Xiang X, Wang ZH, Ye LL, et al. Co-infection of SARS-COV-2 and influenza A virus: a case series and fast review. *Curr Med Sci* 2021; 41(1):51-57. <https://doi.org/10.1007/s11596-021-2317-2> [published Online First: 2021/02/15]
  13. Tong XL, Xu XM, Lu GY, et al. Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China. *BMC Infect Dis*. 2021;21(1):341.
  14. Stowe J, Tessier E, Zhao H, et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. *Int J Epidemiol* 2021;50(4): 1124-1133. <https://doi.org/10.1093/ije/dyab081> [published Online First: 2021/05/05]
  15. Centers for Disease Control (CDC). Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. (Accessed 15 September 2021). Available from: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Coadministration>
  16. Kroger A, Bahta L & Hunter P General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP); 2019. Accessed on [9 June 2021]
  17. Toback SEG, Cosgrove C, Galloway J, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines. MedRxiv 2021 [published Online First: 060921]
  18. Australian Government Department of Health. Updated ATAGI advice on administering seasonal influenza vaccines in 2021. (Accessed 15 June 2021) Available from: <https://www.health.gov.au/news/updated-atagi-advice-on-administering-seasonal-influenza-vaccines-in-2021>
  19. Lee K, Jalal H, Raviotta JM, et al. Predicting the impact of low influenza activity in 2020 on population immunity and future influenza season in the United States. MedRxiv 2021 preprint doi: <https://doi.org/10.1101/2021.08.29.21262803>

**How to cite this article:** McCauley J, Barr IG, Nolan T, Tsai T, Rockman S, Taylor B. The importance of influenza vaccination during the COVID-19 pandemic. *Influenza Other Respi Viruses*. 2022;16(1):3-6. doi:10.1111/irv.12917